Jenkins D J, Taylor R H, Goff D V, Fielden H, Misiewicz J J, Sarson D L, Bloom S R, Alberti K G
Diabetes. 1981 Nov;30(11):951-4. doi: 10.2337/diab.30.11.951.
Fifty-gram carbohydrate tolerance tests were performed on healthy volunteers to test the activity and specificity of an alpha-glucoside hydrolase inhibitor, acarbose (BAY g 5421). Two hundred milligrams acarbose reduced the area under the blood glucose response curve by 89% (P less than 0.001) after sucrose by 80% (P less than 0.002) after starch, by 19% (N.S.) after maltose, with no effect on glucose. Breath hydrogen measurements indicated an almost complete malabsorption of the sucrose. At 50 mg acarbose, some reduction in blood glucose and insulin response to sucrose was still seen, but no significant hydrogen production. It is suggested that at lower doses, acarbose may prolong the time course over which carbohydrate is absorbed as does dietary fiber; as with fiber, it may be a useful adjunct to diabetic therapy.
对健康志愿者进行了50克碳水化合物耐量试验，以测试α-葡萄糖苷水解酶抑制剂阿卡波糖（BAY g 5421）的活性和特异性。200毫克阿卡波糖使蔗糖后血糖反应曲线下面积降低89%（P<0.001），淀粉后降低80%（P<0.002），麦芽糖后降低19%（无统计学意义），对葡萄糖无影响。呼出气氢气测量表明蔗糖几乎完全吸收不良。50毫克阿卡波糖时，仍可见血糖和胰岛素对蔗糖反应有所降低，但无明显氢气产生。提示较低剂量时，阿卡波糖可能像膳食纤维一样延长碳水化合物吸收的时间过程；与纤维一样，它可能是糖尿病治疗的有用辅助药物。
